|
WO2021037013A1
|
|
Novel application of phenothiazines or compound having similar structure in pharmaceutics
|
|
WO2020239118A1
|
|
M1 virus mutant and use thereof
|
|
AU2019272379A1
|
|
Use of proteasome inhibitor and alphavirus in preparation of anti-tumor medicament
|
|
WO2019129235A1
|
|
Application of e3 ligase inhibitor and oncolytic virus in preparing anti-tumor drug
|
|
AU2018393435A1
|
|
Use of mevalonate metabolic pathway inhibitor and alphavirus in preparing anti-tumor drug
|
|
WO2019129232A1
|
|
Application of cdk inhibitor and oncolytic virus in preparation of antitumor drug
|
|
WO2019129233A1
|
|
Use of parp inhibitor and oncolytic virus in preparing anti-tumor drug
|
|
TW201929857A
|
|
Use of aurora kinase inhibitor and alphavirus in preparing anti-tumor drug
|
|
US2019183948A1
|
|
Use of bcl-xl inhibitor and oncolytic virus in preparation of antitumor drug
|
|
US2019167641A1
|
|
Use of vcp inhibitor and oncolytic virus in the preparation of an anti-tumor drug
|
|
CN106265764A
|
|
The application in preparing antitumor drug of IAP inhibitor and oncolytic virus
|
|
WO2017036284A1
|
|
Combined application of direct or indirect agonist of epac and oncolytic virus
|
|
WO2017107319A1
|
|
Application of chrysophanol or its derivatives and oncolytic virus in preparing anti-tumor drugs
|
